Evidence mapPaperPMID 41008615Full record

ReviewBiomolecules2025

Natural Compounds as Modulators of Ferroptosis: Mechanistic Insights and Therapeutic Prospects in Breast Cancer.

Haotong He, Haoyang Yu, Hefeng Zhou, Guozhen Cui, Min Shao

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haotong HeBasic Teaching Department, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.
Haoyang YuBasic Teaching Department, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.
Hefeng ZhouDepartment of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.
Guozhen CuiDepartment of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.ORCID 0000-0002-7639-2456
Min ShaoDepartment of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China.

Funding

Guizhou Provincial Basic Research Program (Natural Science) QKH-JC-ZK[2021]ZD018
6 · The paper itself

Abstract

Breast cancer is the most prevalent malignant tumor in women. However, its clinical management is severely hindered by three interconnected challenges that limit long-term survival: treatment resistance, metastatic dissemination, and immunological evasion. Ferroptosis, an iron-dependent form of regulated cell death, is emerging as a novel strategy to overcome these obstacles. Furthermore, it demonstrates significant potential in inhibiting tumor metastasis and modifying the anti-tumor immune microenvironment, which provides a novel approach to address the core dilemma of breast cancer. Natural products have emerged as significant sources of ferroptosis inducers owing to their distinctive chemical variety, multi-target regulatory capabilities, and acceptable safety profile. Data increasingly indicates that several natural compounds can function as effective inducers or sensitizers of ferroptosis cell death. This review provides a thorough evaluation of current progress in harnessing natural ingredients to trigger ferroptosis for breast cancer treatment. It also elucidates the fundamental molecular mechanisms. Furthermore, it encapsulates therapeutic efficacy in preclinical models. Ultimately, it rigorously evaluates existing constraints and delineates potential and barriers for clinical translation.

Indexed as

Antineoplastic AgentsBiological ProductsBreast NeoplasmsFerroptosisAnimalsFemaleHumansTumor MicroenvironmentAntineoplastic AgentsBiological Productsbreast cancerdrug resistanceferroptosisferroptosis inducerslead compoundsnatural compoundsphytochemicals

Identifiers

PMID41008615
PMCPMC12467155

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.